Format

Send to

Choose Destination
Mol Cancer. 2015 Jun 11;14:119. doi: 10.1186/s12943-015-0384-3.

Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.

Chang DK1,2, Moniz RJ3,4, Xu Z5, Sun J6,7, Signoretti S8,9, Zhu Q10,11, Marasco WA12,13.

Author information

1
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, USA. De-Kuan_Chang@dfci.harvard.edu.
2
Department of Medicine, Harvard Medical School, 25 Shattuck Street, Boston, MA, USA. De-Kuan_Chang@dfci.harvard.edu.
3
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, USA. raymond.moniz@merck.com.
4
Department of Medicine, Harvard Medical School, 25 Shattuck Street, Boston, MA, USA. raymond.moniz@merck.com.
5
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, USA. xu.zhongyao@sinopath.cn.
6
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, USA. Jiusong_Sun@DFCI.HARVARD.EDU.
7
Department of Medicine, Harvard Medical School, 25 Shattuck Street, Boston, MA, USA. Jiusong_Sun@DFCI.HARVARD.EDU.
8
Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, USA. SSIGNORETTI@PARTNERS.ORG.
9
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. SSIGNORETTI@PARTNERS.ORG.
10
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, USA. Quan_Zhu@dfci.harvard.edu.
11
Department of Medicine, Harvard Medical School, 25 Shattuck Street, Boston, MA, USA. Quan_Zhu@dfci.harvard.edu.
12
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, USA. wayne_marasco@dfci.harvard.edu.
13
Department of Medicine, Harvard Medical School, 25 Shattuck Street, Boston, MA, USA. wayne_marasco@dfci.harvard.edu.

Abstract

BACKGROUND:

Carbonic anhydrase (CA) IX is a surface-expressed protein that is upregulated by the hypoxia inducible factor (HIF) and represents a prototypic tumor-associated antigen that is overexpressed on renal cell carcinoma (RCC). Therapeutic approaches targeting CAIX have focused on the development of CAIX inhibitors and specific immunotherapies including monoclonal antibodies (mAbs). However, current in vivo mouse models used to characterize the anti-tumor properties of fully human anti-CAIX mAbs have significant limitations since the role of human effector cells in tumor cell killing in vivo is not directly evaluated.

METHODS:

The role of human anti-CAIX mAbs on CAIX(+) RCC tumor cell killing by immunocytes or complement was tested in vitro by antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP) as well as on CAIX(+) RCC cellular motility, wound healing, migration and proliferation. The in vivo therapeutic activity mediated by anti-CAIX mAbs was determined by using a novel orthotopic RCC xenograft humanized animal model and analyzed by histology and FACS staining.

RESULTS:

Our studies demonstrate the capacity of human anti-CAIX mAbs that inhibit CA enzymatic activity to result in immune-mediated killing of RCC, including nature killer (NK) cell-mediated ADCC, CDC, and macrophage-mediated ADCP. The killing activity correlated positively with the level of CAIX expression on RCC tumor cell lines. In addition, Fc engineering of anti-CAIX mAbs was shown to enhance the ADCC activity against RCC. We also demonstrate that these anti-CAIX mAbs inhibit migration of RCC cells in vitro. Finally, through the implementation of a novel orthotopic RCC model utilizing allogeneic human peripheral blood mononuclear cells in NOD/SCID/IL2Rγ(-/-) mice, we show that anti-CAIX mAbs are capable of mediating human immune response in vivo including tumor infiltration of NK cells and activation of T cells, resulting in inhibition of CAIX(+) tumor growth.

CONCLUSIONS:

Our findings demonstrate that these novel human anti-CAIX mAbs have therapeutic potential in the unmet medical need of targeted killing of HIF-driven CAIX(+)RCC. The orthotopic tumor xenografted humanized mouse provides an improved model to evaluate the in vivo anti-tumor capabilities of fully human mAbs for RCC therapy.

PMID:
26062742
PMCID:
PMC4464115
DOI:
10.1186/s12943-015-0384-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center